

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

APPLN. NO.

10/594,436

ATTY. DKT. NO.

1050-4

APPLICANT

YOSHITAKE et al.

FILING DATE

September 26, 2006

GROUP

1611

FOREIGN PATENT DOCUMENTS

							TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO		
92/22284	12/1992	WO			X			
99/55158	11/1999	WO						
01/28559	04/2001	WO			X			
01/58433	08/2001	WO						
2004/066982	08/2004	WO						
2005/027880	03/2005	WO						
2005/092336	10/2005	WO					abstract	
2006/011159	02/2006	WO						
2006/042277	04/2006	WO						
2007/037259	04/2007	WO					abstract	
2007/072503	06/2007	WO						
2008/002567	01/2008	WO						
2008/067037	06/2008	WO						

OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)

	Abrahamsson et al. "Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon" Int'l J. Pharm. 140:229-235 (1996).
	Lew et al. "An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810)" Alimentary Pharmacol. & Therap. 12:667-672 (1998).
	Lew "Pharmacokinetic concerns in the selection of anti-ulcer therapy" Alimentary Pharmacol. & Therap. 13:11-16 (1999).
	Mallinckrodt Chemicals "MSDS for magnesium chloride" (01/2006).
	Ohning et al. "Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection" Alimentary Pharmacol. & Therap. 14:701-708 (2000).
	Yasuda et al. "Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers" Int'l J. Clin. Pharmacol. Therap. 32:466-473 (1994).
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)